ARTICLE | Preclinical News
Turning cancer cells against their own kind
July 11, 2018 9:18 PM UTC
To overcome hurdles facing cancer cell-based therapies such as self-toxicity and long-term persistence, researchers from Brigham and Women's Hospital and colleagues developed a two-part therapy by pairing tumor cells delivering a receptor-targeted anticancer agent with a suicide system.
Harnessing cancer cells as therapies is advantageous compared with stem cell-based therapies because the cancer cells have enhanced homing toward the primary tumor site and prolonged survival...
BCIQ Company Profiles
BCIQ Target Profiles
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)